source
- Sionna's CF add-on pill fails to improve outcomes in Phase 2 trial with TrikaftaSionna Therapeutics reported that its experimental cystic fibrosis pill, SION-719, did not provide any additional benefit when combined with Vertex Pharmaceuticals' Trikafta in a Phase 2 study. Th…
- Biogen’s ALS drug shows symptom improvement in some patients three years after approvalBiogen’s antisense therapy tofersen, marketed as Qalsody, received FDA approval three years ago as the first treatment to target a genetic form of ALS linked to the SOD1 gene. Since then, a number…